NO981430L - Avkortet gliacellelinjeavledet neurotrof faktor - Google Patents

Avkortet gliacellelinjeavledet neurotrof faktor

Info

Publication number
NO981430L
NO981430L NO981430A NO981430A NO981430L NO 981430 L NO981430 L NO 981430L NO 981430 A NO981430 A NO 981430A NO 981430 A NO981430 A NO 981430A NO 981430 L NO981430 L NO 981430L
Authority
NO
Norway
Prior art keywords
neurotrophic factor
derived neurotrophic
glial cell
truncated
proteins
Prior art date
Application number
NO981430A
Other languages
English (en)
Other versions
NO981430D0 (no
NO322521B1 (no
Inventor
Shaw-Fen Sylvia Hu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO981430D0 publication Critical patent/NO981430D0/no
Publication of NO981430L publication Critical patent/NO981430L/no
Publication of NO322521B1 publication Critical patent/NO322521B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO19981430A 1995-09-28 1998-03-30 Avkortet gliacellelinjeavledet neurotrof faktor (GDNF)-proteinprodukt, plynukleotid som koder for dette, vektor omfattende polynukleotidet, anvendelse av GDNF-proteinproduktet for fremstilling av medikament, anvendelse av nebnte polynukleotid for fremstilling av medikament, anvendelse av celle som er transformert med polynukleotidet for fremstilling av medikament, prokaryot eller eukaryot vertscelle som er transfektert med polynukleotidet, fremgangsmate for fremstilling av avkortet GDNF-protein, farmasoytisk preparat som omfatter dette og fremgangsmate for fremstilling av preparatet. NO322521B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/535,681 US6184200B1 (en) 1995-09-28 1995-09-28 Truncated glial cell line-derived neurotrophic factor
PCT/US1996/014915 WO1997011964A1 (en) 1995-09-28 1996-09-16 Truncated glial cell line-derived neurotrophic factor

Publications (3)

Publication Number Publication Date
NO981430D0 NO981430D0 (no) 1998-03-30
NO981430L true NO981430L (no) 1998-03-30
NO322521B1 NO322521B1 (no) 2006-10-16

Family

ID=24135310

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19981430A NO322521B1 (no) 1995-09-28 1998-03-30 Avkortet gliacellelinjeavledet neurotrof faktor (GDNF)-proteinprodukt, plynukleotid som koder for dette, vektor omfattende polynukleotidet, anvendelse av GDNF-proteinproduktet for fremstilling av medikament, anvendelse av nebnte polynukleotid for fremstilling av medikament, anvendelse av celle som er transformert med polynukleotidet for fremstilling av medikament, prokaryot eller eukaryot vertscelle som er transfektert med polynukleotidet, fremgangsmate for fremstilling av avkortet GDNF-protein, farmasoytisk preparat som omfatter dette og fremgangsmate for fremstilling av preparatet.

Country Status (24)

Country Link
US (5) US6184200B1 (no)
EP (1) EP0920448B1 (no)
JP (3) JP4153036B2 (no)
KR (1) KR100334739B1 (no)
CN (1) CN1283659C (no)
AT (1) ATE314389T1 (no)
AU (1) AU707528B2 (no)
CA (1) CA2232749C (no)
CZ (1) CZ297326B6 (no)
DE (1) DE69635675T2 (no)
DK (1) DK0920448T3 (no)
EA (1) EA001204B1 (no)
ES (1) ES2255713T3 (no)
HU (1) HU226220B1 (no)
IL (6) IL144018A0 (no)
MX (1) MX9802278A (no)
NO (1) NO322521B1 (no)
NZ (1) NZ318697A (no)
SI (1) SI0920448T1 (no)
SK (1) SK288094B6 (no)
TW (1) TW570926B (no)
UA (1) UA66339C2 (no)
WO (1) WO1997011964A1 (no)
ZA (1) ZA968087B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6507788B1 (en) * 1999-02-25 2003-01-14 Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function
US6897061B1 (en) * 2000-06-16 2005-05-24 Spinal Cord Society Transdifferentiation of glial cells
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US7245117B1 (en) 2004-11-01 2007-07-17 Cardiomems, Inc. Communicating with implanted wireless sensor
AU2004283053A1 (en) 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of Parkinson's Disease
CN1897977A (zh) * 2003-10-20 2007-01-17 Ns基因公司 帕金森氏病的体内基因治疗
CN101043899B (zh) 2004-08-19 2011-03-30 比奥根艾迪克Ma公司 重折叠转化型生长因子beta家族蛋白
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
CN101534847A (zh) * 2006-08-04 2009-09-16 普罗龙药品公司 修饰型促红细胞生成素
WO2008100966A1 (en) * 2007-02-12 2008-08-21 The Research Foundation Of State University Of New York Gdnf-derived peptides
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
US8446454B2 (en) * 2007-05-21 2013-05-21 Polycom, Inc. Dynamic adaption of a continuous presence videoconferencing layout based on video content
FI20070808A0 (fi) * 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
UA112981C2 (uk) * 2011-04-11 2016-11-25 Елі Ліллі Енд Компані Варіант людського gdnf
US10376562B2 (en) 2013-03-15 2019-08-13 The Jackson Laboratory Methods for promoting wound healing and hair growth comprising GDNF administration
RU2561050C2 (ru) 2013-08-28 2015-08-20 Федеральное государственное бюджетное учреждение науки Институт биофизики клетки Российской академии наук (ИБК РАН) Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера
US11912750B2 (en) 2016-11-10 2024-02-27 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
US20230022970A1 (en) * 2019-12-19 2023-01-26 Transfert Plus, Société En Commandite Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
CA3238867A1 (en) 2021-11-29 2023-06-01 Shanghai Regenelead Therapies Co., Ltd. Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US5229500A (en) 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
CA1332433C (en) 1989-09-29 1994-10-11 Robert L. Sutherland Ski structure and binding therefor
EP0676470A1 (en) 1989-10-16 1995-10-11 Amgen Inc. Stem cell factor
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5202428A (en) 1990-06-20 1993-04-13 The Salk Institute For Biological Studies DNA encoding neurotropic growth factor
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
WO1993006116A1 (en) 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
AU1443095A (en) 1993-12-22 1995-07-10 University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product

Also Published As

Publication number Publication date
NZ318697A (en) 1999-09-29
ZA968087B (en) 1997-06-12
JPH11512709A (ja) 1999-11-02
JP4153036B2 (ja) 2008-09-17
HK1021823A1 (en) 2000-07-07
US6184200B1 (en) 2001-02-06
IL123761A (en) 2005-12-18
IL144488A0 (en) 2002-05-23
EP0920448B1 (en) 2005-12-28
IL218336A0 (en) 2012-04-30
US20040127419A1 (en) 2004-07-01
UA66339C2 (uk) 2004-05-17
NO981430D0 (no) 1998-03-30
CZ297326B6 (cs) 2006-11-15
AU7074696A (en) 1997-04-17
US20040214776A1 (en) 2004-10-28
WO1997011964A1 (en) 1997-04-03
CZ88298A3 (cs) 1999-02-17
DE69635675D1 (de) 2006-02-02
HUP9802262A2 (hu) 1999-01-28
US7390781B2 (en) 2008-06-24
JP2010279360A (ja) 2010-12-16
KR100334739B1 (ko) 2002-09-17
MX9802278A (es) 1998-08-30
NO322521B1 (no) 2006-10-16
US20040254114A1 (en) 2004-12-16
IL144018A (en) 2012-04-30
ATE314389T1 (de) 2006-01-15
CN1197461A (zh) 1998-10-28
CA2232749A1 (en) 1997-04-03
EA001204B1 (ru) 2000-12-25
KR19990063825A (ko) 1999-07-26
US20110251267A1 (en) 2011-10-13
DK0920448T3 (da) 2006-04-10
HU226220B1 (hu) 2008-06-30
JP5241037B2 (ja) 2013-07-17
CA2232749C (en) 2003-03-25
SK38998A3 (en) 1999-07-12
JP4909843B2 (ja) 2012-04-04
IL144018A0 (en) 2002-04-21
EP0920448A1 (en) 1999-06-09
AU707528B2 (en) 1999-07-15
IL123761A0 (en) 1998-10-30
SI0920448T1 (sl) 2006-04-30
JP2008067699A (ja) 2008-03-27
ES2255713T3 (es) 2006-07-01
CN1283659C (zh) 2006-11-08
IL144488A (en) 2006-12-31
HUP9802262A3 (en) 2001-01-29
TW570926B (en) 2004-01-11
EA199800301A1 (ru) 1998-10-29
US7611865B2 (en) 2009-11-03
DE69635675T2 (de) 2006-07-06
SK288094B6 (sk) 2013-07-02

Similar Documents

Publication Publication Date Title
NO981430D0 (no) Avkortet gliacellelinjeavledet neurotrof faktor
DK1210411T3 (da) Sammensætninger og fremgangsmåder til forbedret celledyrkning
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
PT1428878E (pt) Processo para a produção e purificação de eritropoietina
WO2002029083A3 (en) Industrial-scale serum-free production of recombinant proteins in mammalian cells
UA81398C2 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
TW200505939A (en) Process for production of cyclic peptides
ATE437951T1 (de) Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
DE69638077D1 (de) Bakterielle Produktion von Interferon-beta Polypeptiden
DE69637844D1 (de) Neues tgf-beta-ahnliches cytokin
DK0986644T3 (da) Fremstilling af erythropoietin ved endogen genaktivering med virale promotorer
BRPI0410562A (pt) molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo
ATE531789T1 (de) Zellmembranenveränderung
ES2055611T3 (es) Pdgf resistente a proteasas y metodos de uso.
IL126221A0 (en) Scf analog compositions and methods
GB2322132B (en) Keratinocyte growth factor-2 products
DK1000154T3 (da) Identificering af humane cellelinjer til produktion af humane proteiner ved endogen genaktivering
ATE246935T1 (de) Zns neuroregenerative zusammensetzungen und deren verwendungen
ES2052513T3 (es) Nuevos polipeptidos, su fabricacion y empleo.
DK0977859T3 (da) Den neurotrofiske faktor NNT-1
EP1440085B8 (de) Transiente immortalisierung von zellen durch onkogenproteine oder telomerproteine
WO2002068668A3 (en) Compositions and methods for production cell culture
DE60044528D1 (de) Bazillus zelle für die herstellung von proteinen
NO910981L (no) Peptidforbindelser.
CY1117550T1 (el) Ανευ-τροφοδοτικων κυτταρων, ανευ-ξενογενων συστατικων συστημα καλλιεργειας για ανθρωπινα εμβρυονικα βλαστοκυτταρα

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees